nur 2,3 mio börsenwert versprechen bei einer vollzugsmeldung zum investor renditechancen
Anzeige
Meldung des Tages: +15 % an einem Tag – und dieser Ausbruch hat gerade erst begonnen
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
1 2 3 4 5 6 7 8 9
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter 1 2 3 4 5 6 7 8 9
Medx Health Blockbuster Potential !
Beiträge:
203
Zugriffe: 46.462 / Heute: 11
Zugriffe: 46.462 / Heute: 11
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +114,05%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +51,17%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +50,94%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +50,55%
Kanada mit guten Umsätzen auf Tageshoch und damit neuem Jahreshoch geschlossen.
Schlußkurs über 200 Tagelinie (1. SK ü. GD 200 seit fast 12 Monaten) !
Charttechnisch freigeschossen
Schlußkurs über 200 Tagelinie (1. SK ü. GD 200 seit fast 12 Monaten) !
Charttechnisch freigeschossen
da wird es spannend in Sachen News. Die starken Umsätze der letzten Tage. der steigende Kurs der Deal mit dem Investmenthaus und die extrem niedrige Börsenbewertung versprechen hier gute Chancen auf neue Jahreshochs der Aktie. Der Kurs dürfte also deutlich nziehen. Ziel zwischen. 0,5 - 0,8 Potential sehr hoch. kurzfristig
MedX Laser und die MedX Phototherapie vor dem absoluten Durchbruch. Die MedX Laser
Technologie sowie Patente Millionen Marktwert. Laser gegen Krebs für MedX Laser eine Meilenstein
News.
www.uchospitals.edu/news/2013/20130305-focal-therapy.html
Focal therapy offers middle ground for some prostate cancer patients
March 5, 2013
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a small insertion and guided into the prostate by magnetic resonance imaging, to burn away cancerous cells in the prostate.
A small, phase 1 trial, published early online in the journal "Radiology", found that this approach, designed to treat just the diseased portion of the prostate rather than removing or irradiating the entire gland, is safe and can be performed without the troubling complications associated with more aggressive therapies.
None of the nine men treated in the study had a significant side effect. Six months after therapy, seven of the nine patients (78%) no longer had evidence of cancerous tissue in biopsies of the treated area.
“Focal therapy is the male version of a lumpectomy for breast cancer,” said study author Scott Eggener, MD, associate professor of surgery at the University of Chicago Medicine. “Rather than removing the entire organ, we are testing this less-invasive way of destroying just the cancer and leaving healthy tissue in place.”
“This experimental approach appears to combine the most attractive element of treatment, eradication of the cancer, with the most appealing element of active surveillance, maintaining quality of life,” said Aytekin Oto, MD, professor of radiology and chief of abdominal imaging at the University of Chicago Medicine. “These early safety results are promising, but we definitely need longer-term data.”
More than 2 million American men have been diagnosed with prostate cancer. Due to prostate specific antigen testing (PSA), most of these cancers are detected early, long before they cause symptoms. Because this cancer occurs primarily in older men, treatment with radiation or surgery is not always necessary as these are man are much more likely to die from another cause than from prostate cancer.
But many healthy men who are relatively young, with a life expectancy greater than 10 years, are not comfortable deferring treatment of a potentially lethal disease. Surgery and radiation can often cure the cancer, but can cause side effects, such as incontinence, impotence and decreased bowel function.
This study enrolled nine men with biopsy-confirmed, low-risk prostate cancers (Gleason score 6 or 7, less than 12 mm of cancer) with an MRI of the prostate showing a small area of cancer. Patients were treated under conscious sedation while lying in an MRI scanner. After injecting a local anesthetic, the physicians inserted a small catheter across the perineum and used it to guide a tiny optical fiber, the laser and a cooling device into the prostate.
Under MRI guidance, the laser was positioned within the cancer and used to heat the area to a temperature that would kill cancer cells. The team checked the temperatures outside the treatment region every five seconds to protect healthy tissue, especially those near critical structures such as the urethra and rectal wall.
The entire procedure took less than four hours. That decreased to 2.5 hours as the team gained experience. The actual heat treatment averaged 4.3 minutes. All patients left the hospital the same day.
No patient had a major complication or a serious adverse effect. Average scores for urinary or sexual function were not significantly different one, three or six months after treatment. No patient had symptoms of rectal wall damage.
Biopsies of the treated areas six months after the procedure found no evidence of prostate cancer in seven of the nine patients (78%). The other two patients had small (2.5 mm and 1 mm) remaining cancers.
These are preliminary results, the authors caution, following a small number of patients for a short time. It will take much longer follow-up, the authors say, to fully evaluate this approach.
Focal laser ablation is the latest in a series of efforts to target just the cancer cells and preserve normal areas of prostate. It appears to offer “measurable advantages over other ablative therapies for focal prostate treatment, namely that we can visualize our treatment as it is happening,” according to the study authors.
Laser-induced heating can destroy cancer cells with little damage beyond the precisely targeted zone. The approach is well suited for prostate tissue and can be carefully watched in real-time with magnetic resonance imaging, which can also monitor the generation and consequences of the heat treatment.
A phase 2 trial of this procedure, sponsored by the National Institutes of Health, is now underway at the University of Chicago Medicine. The physicians hope to enroll 27 patients. Details are available at the NIH’sClinicalTrials.gov
website, identifier: NCT01792024
.
The paper, “MR Imaging-guided Focal Laser Ablation for Prostate Cancer: Phase I Trial,” appears as an early release in "Radiology
". The study was supported by a research grant from the Partnership for Cures Foundation and by Visualase, the manufacturer of the imaging software and laser ablation tools used in this study. Additional authors include Gregory Karczmar and Walter Stadler of the University of Chicago, and Ila Sethi, Roger McNichols, Karko Ivancevic and Sydeaka Watson of Visualase.
*The University of Chicago Medicine*
Communications
950 E. 61st Street, Third Floor
Chicago, IL 60637
Phone (773) 702-0025 Fax (773) 702-3171
Related Links
* Scott Eggener, MD
* Aytekin Oto, MD
* Prostate Cancer Care
Social Media
* Twitter
* Facebook
* Science Life Blog
* YouTube
Press Contact
*John Easton*
(773) 702-0025
john.easton@uchospitals.edu
Technologie sowie Patente Millionen Marktwert. Laser gegen Krebs für MedX Laser eine Meilenstein
News.
www.uchospitals.edu/news/2013/20130305-focal-therapy.html
Focal therapy offers middle ground for some prostate cancer patients
March 5, 2013
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a small insertion and guided into the prostate by magnetic resonance imaging, to burn away cancerous cells in the prostate.
A small, phase 1 trial, published early online in the journal "Radiology", found that this approach, designed to treat just the diseased portion of the prostate rather than removing or irradiating the entire gland, is safe and can be performed without the troubling complications associated with more aggressive therapies.
None of the nine men treated in the study had a significant side effect. Six months after therapy, seven of the nine patients (78%) no longer had evidence of cancerous tissue in biopsies of the treated area.
“Focal therapy is the male version of a lumpectomy for breast cancer,” said study author Scott Eggener, MD, associate professor of surgery at the University of Chicago Medicine. “Rather than removing the entire organ, we are testing this less-invasive way of destroying just the cancer and leaving healthy tissue in place.”
“This experimental approach appears to combine the most attractive element of treatment, eradication of the cancer, with the most appealing element of active surveillance, maintaining quality of life,” said Aytekin Oto, MD, professor of radiology and chief of abdominal imaging at the University of Chicago Medicine. “These early safety results are promising, but we definitely need longer-term data.”
More than 2 million American men have been diagnosed with prostate cancer. Due to prostate specific antigen testing (PSA), most of these cancers are detected early, long before they cause symptoms. Because this cancer occurs primarily in older men, treatment with radiation or surgery is not always necessary as these are man are much more likely to die from another cause than from prostate cancer.
But many healthy men who are relatively young, with a life expectancy greater than 10 years, are not comfortable deferring treatment of a potentially lethal disease. Surgery and radiation can often cure the cancer, but can cause side effects, such as incontinence, impotence and decreased bowel function.
This study enrolled nine men with biopsy-confirmed, low-risk prostate cancers (Gleason score 6 or 7, less than 12 mm of cancer) with an MRI of the prostate showing a small area of cancer. Patients were treated under conscious sedation while lying in an MRI scanner. After injecting a local anesthetic, the physicians inserted a small catheter across the perineum and used it to guide a tiny optical fiber, the laser and a cooling device into the prostate.
Under MRI guidance, the laser was positioned within the cancer and used to heat the area to a temperature that would kill cancer cells. The team checked the temperatures outside the treatment region every five seconds to protect healthy tissue, especially those near critical structures such as the urethra and rectal wall.
The entire procedure took less than four hours. That decreased to 2.5 hours as the team gained experience. The actual heat treatment averaged 4.3 minutes. All patients left the hospital the same day.
No patient had a major complication or a serious adverse effect. Average scores for urinary or sexual function were not significantly different one, three or six months after treatment. No patient had symptoms of rectal wall damage.
Biopsies of the treated areas six months after the procedure found no evidence of prostate cancer in seven of the nine patients (78%). The other two patients had small (2.5 mm and 1 mm) remaining cancers.
These are preliminary results, the authors caution, following a small number of patients for a short time. It will take much longer follow-up, the authors say, to fully evaluate this approach.
Focal laser ablation is the latest in a series of efforts to target just the cancer cells and preserve normal areas of prostate. It appears to offer “measurable advantages over other ablative therapies for focal prostate treatment, namely that we can visualize our treatment as it is happening,” according to the study authors.
Laser-induced heating can destroy cancer cells with little damage beyond the precisely targeted zone. The approach is well suited for prostate tissue and can be carefully watched in real-time with magnetic resonance imaging, which can also monitor the generation and consequences of the heat treatment.
A phase 2 trial of this procedure, sponsored by the National Institutes of Health, is now underway at the University of Chicago Medicine. The physicians hope to enroll 27 patients. Details are available at the NIH’sClinicalTrials.gov
website, identifier: NCT01792024
.
The paper, “MR Imaging-guided Focal Laser Ablation for Prostate Cancer: Phase I Trial,” appears as an early release in "Radiology
". The study was supported by a research grant from the Partnership for Cures Foundation and by Visualase, the manufacturer of the imaging software and laser ablation tools used in this study. Additional authors include Gregory Karczmar and Walter Stadler of the University of Chicago, and Ila Sethi, Roger McNichols, Karko Ivancevic and Sydeaka Watson of Visualase.
*The University of Chicago Medicine*
Communications
950 E. 61st Street, Third Floor
Chicago, IL 60637
Phone (773) 702-0025 Fax (773) 702-3171
Related Links
* Scott Eggener, MD
* Aytekin Oto, MD
* Prostate Cancer Care
Social Media
* Science Life Blog
* YouTube
Press Contact
*John Easton*
(773) 702-0025
john.easton@uchospitals.edu
Das ding ist ein ganz schlechter Push.
Man kann schön am Volumen erkennen das es ein "Fake" ist.
Anders gesagt kurz nach dem Starken Volumen ging kurz drauf mehr Volumen wieder heraus obwohl der kurs weiter steigt!
Hier will jemand ganz klar ein paar Ahnungslose anlocken!
Finger weg!!
Das ganze nochmal in einer einfachen Grafik:
Bilderquelle: www.finanzen.net/chart/MedX_Health
(Verkleinert auf 44%) 
Du nennst das Push wer sich allerdings nicht nur oberflächlich mit dem Unternehmen beschäftigt hat weiß im übrigen das der Byron deal positiv gelaufen scheint.
Sämtliche Umsätze sind an der kanadischen Heimatborse. Intraday Umsätze von ca. 4 Millionen infolge guter News als Push zu bezeichnen ist einfach nur peinlich. Byron war eben erfolgreich und ein paar insider gibt es immer. Im übrigen kann jeder seine Meinung schreiben. Auch Kritiker sind gern willkommen . Doch bevor man kritisiert sollte man sich informieren. Danke
Byron will, over a two-month period commencing on the date of signature of the agreement, facilitate MDX's access to capital markets, and identify potential acquisition, divestiture or merger opportunities. In addition, Byron will provide strategic advice to MDX with the intent to maximize shareholder value, assist with introduction to potential strategic investors and assist MDX in structuring future transactions.
Moderation
Zeitpunkt: 30.03.13 15:06
Aktion: Nutzer-Sperre für 1 Tag
Kommentar: 1 Tag Sperre wegen Anlegens einer Doppel-ID - Doppel-ID: Gesprengt
Zeitpunkt: 30.03.13 15:06
Aktion: Nutzer-Sperre für 1 Tag
Kommentar: 1 Tag Sperre wegen Anlegens einer Doppel-ID - Doppel-ID: Gesprengt
Link: Nutzungsbedingungen
Also jetzt mal Butter bei "die " Fische glaubst du das was du geschrieben hast wirklich oder willst du jemanden veräppeln. Was ist denn in der Infusion drin ?
Moderation
Zeitpunkt: 22.03.13 14:37
Aktion: Nutzer-Sperre für 1 Tag
Kommentar: 1 Tag Sperre wegen Anlegens einer Doppel-ID - Doppel-ID: Schwiegermutter
Zeitpunkt: 22.03.13 14:37
Aktion: Nutzer-Sperre für 1 Tag
Kommentar: 1 Tag Sperre wegen Anlegens einer Doppel-ID - Doppel-ID: Schwiegermutter
Link: Nutzungsbedingungen
MedX's HandySana 211 mobile Health Projekt erfährt eine totale Neubewertung. 26 Mrd. Dollar Markt in nur 5 Jahren
www.medxhealth.com/documents/Handy_sana_211_Blurb.pdf
www.crn.de/netzwerke-tk/artikel-98569.html
Mobility-TrendMarkt für mobile Gesundheits-Apps boomt
11.03.2013
Technische Medizinlösungen werden in steigendem Maße als Apps angeboten. Bis 2017 soll der Markt 26 Milliarden US-Dollar schwer werden.Arztsuche-App: »Verbraucher nutzen Smartphones zur Verbesserung der Gesundheitsversorgung«. Der Markt für sogenannte mHealth Dienstleistungen hat die Phase der Kommerzialisierung erreicht. In vier Jahren werden die Umsätze hier 26 Milliarden US-Dollar erreichen. Die Zahl stammt aus dem neuen Bericht »GlobalMobile Health Market Report 2013-2017« des Berliner Beratungsunternehmens Research2guidance.»Unsere Ergebnisse zeigen, dass die lang erwartete mobile Revolution im Gesundheitswesen beginnt. Sowohl Anbieter im Gesundheitswesen als auchVerbraucher nutzen Smartphones zur Verbesserung der Gesundheitsversorgung« erläutert Ralf-Gordon Jahns, Research Director bei Research2guidance.
www.medxhealth.com/documents/Handy_sana_211_Blurb.pdf
www.crn.de/netzwerke-tk/artikel-98569.html
Mobility-TrendMarkt für mobile Gesundheits-Apps boomt
11.03.2013
Technische Medizinlösungen werden in steigendem Maße als Apps angeboten. Bis 2017 soll der Markt 26 Milliarden US-Dollar schwer werden.Arztsuche-App: »Verbraucher nutzen Smartphones zur Verbesserung der Gesundheitsversorgung«. Der Markt für sogenannte mHealth Dienstleistungen hat die Phase der Kommerzialisierung erreicht. In vier Jahren werden die Umsätze hier 26 Milliarden US-Dollar erreichen. Die Zahl stammt aus dem neuen Bericht »GlobalMobile Health Market Report 2013-2017« des Berliner Beratungsunternehmens Research2guidance.»Unsere Ergebnisse zeigen, dass die lang erwartete mobile Revolution im Gesundheitswesen beginnt. Sowohl Anbieter im Gesundheitswesen als auchVerbraucher nutzen Smartphones zur Verbesserung der Gesundheitsversorgung« erläutert Ralf-Gordon Jahns, Research Director bei Research2guidance.
www.rekahealth.com/index.aspx
REKA Pte Ltd, main operation in Singapore, is the developer for H'andy Sana and other mobile ECG series of products.
Mr. Frank Raymakers, Director of Sales, EuropeMr. Raymakers has over 30 years of experience in sales and marketing, with the bulk of them specializing in the medical device industry. Throughout his career, Mr. Raymakers has consistently delivered results in managing sales and distribution networks for medical devices and systems, which encompassed the ambulatory, hospital, and home-care markets. Previously, as the Sales Director at Envitec (now part of Honeywell), Mr. Raymakers took charge of expanding the markets in Europe and the Middle East. While at Envitec, he successfully increased sales under his charge by ten-fold and played a major role in the growth of the company, which in turn led to the acquisition of the company by Honeywell in 2007. Mr. Raymakers went on to serve as the Sales Director for MedX Healthcare, and subsequently Medical Marketing Berlin (MMB). During his time with these two companies, Mr. Raymakers successfully established extensive sales and distribution networks for his companies’ products in the European market, while effectively managing relationships with stakeholders in the industry, such as doctors, distributors, and pharmaceutical companies.Mr. Raymakers can be reached at frank@rekahealth.com.
REKA Pte Ltd, main operation in Singapore, is the developer for H'andy Sana and other mobile ECG series of products.
Mr. Frank Raymakers, Director of Sales, EuropeMr. Raymakers has over 30 years of experience in sales and marketing, with the bulk of them specializing in the medical device industry. Throughout his career, Mr. Raymakers has consistently delivered results in managing sales and distribution networks for medical devices and systems, which encompassed the ambulatory, hospital, and home-care markets. Previously, as the Sales Director at Envitec (now part of Honeywell), Mr. Raymakers took charge of expanding the markets in Europe and the Middle East. While at Envitec, he successfully increased sales under his charge by ten-fold and played a major role in the growth of the company, which in turn led to the acquisition of the company by Honeywell in 2007. Mr. Raymakers went on to serve as the Sales Director for MedX Healthcare, and subsequently Medical Marketing Berlin (MMB). During his time with these two companies, Mr. Raymakers successfully established extensive sales and distribution networks for his companies’ products in the European market, while effectively managing relationships with stakeholders in the industry, such as doctors, distributors, and pharmaceutical companies.Mr. Raymakers can be reached at frank@rekahealth.com.
www.prnewswire.com/news-releases/...-technology-193824341.html
Gelöschter Beitrag.
Einblenden
»
#111
Diese Form der Therapie wird nun auch von großen Health Care Unternehmen entdeckt. GE Healthcare z. B. will im Bereich Sauglingspflege die Phototherapie anwenden.
Auch in der Krebs Therapie wird diese Technologie entdeckt. Der Markt für das Produkt ist ein Milliarde Markt. Weitere Anwendungsbereiche sind wundheilung, Alzheimer, Parkinson usw.
MedX verfügt über ein umfangreiches und innovatives Produktportfolio
im HealthCare Bereich. Nun endlich werden diese Produkte und deren positive TherapieWirkung entdeckt. Für MedX dürfte damit eine aggressive Wachstumsstory in einem Multi MilliardenMarkt beginnen.
www.docstoc.com/docs/124686423/MEDX-ad
MedX Health Corp. (MedX) develops, manufactures and markets phototherapy devices for pain relief and tissue repair. The Company develops, manufactures and distributes low-level laser light technology and light imaging systems, for use in numerous medical settings for tissue repair, including rehab/sports medicine, dentistry, wound care, aesthetics, pain management, and imaging of suspicious moles or lesions. MedX products are used by practitioners in clinics, academic facilities, and hospitals, as well as by professional athletes and sports teams. MedX products include MedX Phototherapy Device, MedX Rehab Console System, MedX Rehab Handheld Laser, MedX superluminous diodes (SLD) Cluster, MedX Rehab Portable Laser, MedX Dental Console System, Oralase Dental Portable Laser, MedXHome System, Acupuncture Console System and Acupuncture Portable Laser. On June 15, 2011, it purchased from Biocompatibles UK Ltd, the worldwide Siascopy assets, which includes MoleMate and related technologies.2013-03-06 01:27:48
en.m.wikipedia.org/wiki/Light_therapy#section_5
Parkinson's disease
Bright light therapy may ease Parkinson's disease
by reducing patients' tremors.[41]
[42]
Alzheimer's disease
A qualitative study
conducted on a 20-person cohort
of women and published in 2011 suggested a positive impact of light therapy on overall cognitive function
in Alzheimer's disease
patients, a preliminary finding requiring larger andquantitative studies
to confirm.[43]
[44]
Auch in der Krebs Therapie wird diese Technologie entdeckt. Der Markt für das Produkt ist ein Milliarde Markt. Weitere Anwendungsbereiche sind wundheilung, Alzheimer, Parkinson usw.
MedX verfügt über ein umfangreiches und innovatives Produktportfolio
im HealthCare Bereich. Nun endlich werden diese Produkte und deren positive TherapieWirkung entdeckt. Für MedX dürfte damit eine aggressive Wachstumsstory in einem Multi MilliardenMarkt beginnen.
www.docstoc.com/docs/124686423/MEDX-ad
MedX Health Corp. (MedX) develops, manufactures and markets phototherapy devices for pain relief and tissue repair. The Company develops, manufactures and distributes low-level laser light technology and light imaging systems, for use in numerous medical settings for tissue repair, including rehab/sports medicine, dentistry, wound care, aesthetics, pain management, and imaging of suspicious moles or lesions. MedX products are used by practitioners in clinics, academic facilities, and hospitals, as well as by professional athletes and sports teams. MedX products include MedX Phototherapy Device, MedX Rehab Console System, MedX Rehab Handheld Laser, MedX superluminous diodes (SLD) Cluster, MedX Rehab Portable Laser, MedX Dental Console System, Oralase Dental Portable Laser, MedXHome System, Acupuncture Console System and Acupuncture Portable Laser. On June 15, 2011, it purchased from Biocompatibles UK Ltd, the worldwide Siascopy assets, which includes MoleMate and related technologies.2013-03-06 01:27:48
en.m.wikipedia.org/wiki/Light_therapy#section_5
Parkinson's disease
Bright light therapy may ease Parkinson's disease
by reducing patients' tremors.[41]
[42]
Alzheimer's disease
A qualitative study
conducted on a 20-person cohort
of women and published in 2011 suggested a positive impact of light therapy on overall cognitive function
in Alzheimer's disease
patients, a preliminary finding requiring larger andquantitative studies
to confirm.[43]
[44]
investox und bondjames hier schreiben ist echt mies. Hoffe dass absolut niemand auf euer Geschreibe hereinfällt und irgendetwas in dieses UN investiert. Irgendwelche scheinbar guten News von irgendwoher hier veröffentlichen, aber auf kritische Fragen nicht eingehen... meiner Meinung nach ein ganz schlechter Push-Versuch.
MedX Health appoints Canitano as president, COO
2013-04-05 10:22 ET - News Release
Mr. Louie Canitano reports
MEDX NAMES LOUIE CANITANO AS PRESIDENT AND CHIEF OPERATING OFFICER
MedX Health Corp.'s board of directors has appointed Louie Canitano as president and chief operating officer effective immediately.
In his new role as president and chief operating officer Mr. Canitano will oversee all operational, financial and corporate aspects of the company and will focus on executing the strategic plan approved by the board. MedX's patented medical device technology for the early detection of skin cancer is the company's leading product and as such will be the focal point of its development and marketing strategy. This product has the potential to create a new and substantial revenue stream for MedX.
Mr. Canitano joined MedX in February, 2010, as executive vice-president, operations. He has a deep understanding of operating emerging growth medical device technology companies, and brings to MedX over 18 years of operational medical device experience focusing on engineering, proprietary intellectual property, management and corporate assignments. Mr. Canitano is uniquely suited to anticipate trends and quickly respond to regulatory changes and financing challenges, and has experience in all sectors including sales and marketing, regulatory, IP, design and development, and also holds a patent surrounding laser therapy. Mr. Canitano began his career with managing G code and Schedule 5-based OHIP physiotherapy and multidisciplinary clinics, introducing and utilizing laser therapy as a palliative modality. He has a bachelor of sciences in natural health sciences.
Mr. Canitano states: "Skin cancer represents the fastest growing form of cancer in the world and affects all age groups. Detecting skin cancer early is the key to long-term survival rates and therefore MedX will seek unique strategic relationships that give ease of access to our technology. This includes partnering with thought leaders, advocacy partners, and strategic channel partners to ensure our technology has global reach."
We seek Safe Harbor.
Quelle: www.stockwatch.com/News/...2056772&symbol=MDX®ion=C
MedX to file late 2012 results, requests MCTO
2013-04-12 14:27 ET - News Release
Mr. Louie Canitano reports
MEDX ANNOUNCES ANTICIPATED DELAY IN ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2012
As a result of delays in being able to obtain financing to secure fees due to its auditors, which financing has now been secured, MedX Health Corp. anticipates that it will be unable to meet its originally scheduled filing of the annual audited consolidated financial statements for the year ended Dec. 31, 2012, the management's discussion and analysis for the for the year, and relevant chief executive officer and chief financial officer certifications within the time prescribed by securities regulations, namely April 30, 2013. Management has taken steps to resolve the difficulties, and believes that as a result it will be able to file the annual audited consolidated financial statements, management's discussion and analysis, and CEO and CFO certifications for the year ended Dec. 31, 2012, by May 17, 2013.
The company has made an application to the Ontario Securities Commission, as its principal regulator, for issuance of a management cease-trade order pursuant to National Policy 12-203, and intends to comply with its obligations to satisfy the provisions of the alternative information guidelines as set out in National Policy 12-203 for so long as it remains in default.
MedX is not the subject of any insolvency proceeding.
There is no other material information that has not been generally disclosed.
We seek Safe Harbor.
Quelle: www.stockwatch.com/News/...2058606&symbol=MDX®ion=C
besser gesagt, wie soll/wird das interpretiert? Ist das gut? Auf den Kurs scheints ja keine Auswirkungen zu haben...
interpretationsansätze bleiben jedem selbst überlassen.. "MedX is not the subject of any insolvency proceeding" mal sehn was das bedeutet..
www.boerse-frankfurt.de/de/aktien/...th+corp+CA5850901037/news
Dear ......,
Thank you for your patience and co-operation regarding the CTO for MDX.
I have enclosed below as an pdf attachment the press release that was issued yesterday indicating the completion and filing of the Audited Financials for the Year Ended December 31, 2012. The actual Statements and MD & A is available on: http://www.sedar.com/.
Based on the all of the provincial regulators requirements which includes but not limited to the OSC the TSX, BCSC, ASC, etc., given that we have now filed and submitted all of the necessary forms and fees I expect we should hopefully be up and trading sometime next week.
Let me know if you require any additional assistance or information with respect to this matter.
Regards,
Louie Canitano
President and Chief Operating Officer
Weiters zu den Zahlen: http://www.stockwatch.com - Canada - Symbol MDX ...
Und dann muss der Kurs nur noch ein bisschen steigen :-)
MedX Health reinstated for trading
2013-05-31 18:40 ET - Cease Trade Company Rescinded
Further to the TSX Venture Exchange bulletin dated May 6, 2013, the exchange has been advised that the cease trade order issued by the Ontario Securities Commission on May 6, 2013, has been revoked.
Effective at the open on Monday, June 3, 2013, trading will be reinstated in the securities of the company.
seen on: www.stockwatch.com/News/...2077406&symbol=MDX®ion=C
wird unsere medx jetzt schon übernommen ?
BC Technical Acquires MEDX
www.prnewswire.com/news-releases/...quires-medx-210687151.html
BC Technical Acquires MEDX
www.prnewswire.com/news-releases/...quires-medx-210687151.html
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Medx Health Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 202 | Medx Health Blockbuster Potential ! | Investox | Resol_i | 07.11.13 10:58 |